Drug Trial Radar · NCT07105371
Patients With ALS and Other Motor Disorders Will be Treated With Umbilical or Placental Mesenchymal Cell Exosome Solution
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Jul 14, 2024
Primary completion
Oct 1, 2026
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- The Foundation for Orthopaedics and Regenerative MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with ALS and other Motor Discorders will be treated with mesenchymal cell exosome solution.
Conditions
- Motor Disorders
Interventions
Exosome SecretomeBiological
This is an intranasal treatment of exosomes derived from Umbilical or Placental Derived Mesenchymal Stem Cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ALSFRS-R ResultsTime frame: from enrollment until 6 months after treatment
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Prodromos Stem Cell Institute
Naples, Florida
Prodromos Stem Cell Institute
Athens, Greece
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.